Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction Insights from the EXAMINATION trial

S Brugaletta, M Sabate, V Martin-Yuste, M Masotti, Y Shiratori, L Alvarez-Contreras, A Cequier, A Iniguez, A Serra, R Hernandez-Antolin, V Mainar, M (Marco) Valgimigli, M Tespili, P den Heijer, A Bethencourt, N Vazquez, Josep Gomez Lara, B Backx, PWJC (Patrick) Serruys

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)


Background: Few data are available about safety of second generation drug eluting stents in an all-comer ST elevation myocardial infarction (STEMI) population. We sought to investigate the predictors and clinical implications of 1-year stent thrombosis (ST) in patients with STEMI, included in the EXAMINATION trial. Methods and results: The EXAMINATION trial is an all-comer prospective, randomized 1: 1 controlled trial, testing everolimus-eluting stent (EES) vs. cobalt chromium bare metal stent (BMS) in STEMI patients. It included 1498 patients, randomized to EES (n = 751) or BMS (n = 747). At 1 year, definite/probable stent thrombosis, defined according to ARC criteria, occurred in 26 patients (1.73%), including 18 definite and 8 probable events. The incidence of ST was lower in patients treated with EES t Conclusions: ST had low frequency in the first year after implantation of EES/BMS in STEMI patients, but it is associated with adverse events. BMS implantation, lack of ST-segment resolution and high Killip class on admission were independent predictors of 1-year ST. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)2632-2636
Number of pages5
JournalInternational Journal of Cardiology
Issue number3
Publication statusPublished - 2013

Cite this